REFERENCES

• The WHOQOL Group. The World Health Organization Quality of Life Assessment (the WHOQOL): position paper from the World Health Organisation.Soc Sci Med.199541140314098560308
   PubMed Web of Science ®Google Scholar
• BobesJ.Garcia-PortillaMP.Quality of life in schizophrenia. In: Katschnig H, Freeman H, Sartorius N, eds.Quality of Life in Mental Disorders. Chichester, UK: John Wiley & Sons Ltd;2005153168
   Google Scholar
• BobesJ.Current status of quality of life assessment in schizophrenic patients.Eur Arch Psychiatry Clin Neurosc.2001251(suppl 2)ll/38ll/42
   Web of Science ®Google Scholar
• BobesJ.Garcia-PortillaMP.SaizPA.BascaranT.BousoñoM.Quality of life measures in schizophrenia.Eur Psychiatry.20052053135317
   Web of Science ®Google Scholar
• LehmanAF.PostradoLT.RachobaLT.Convergent validation of quality of life assessment for persons with severe mental illness.Qual Life Res.199323273338136797
   PubMed Web of Science ®Google Scholar
• BrowneS.RoeM.LaneA.et al.Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia.Acta Psychiatr Scand.1996941181248883573
   PubMed Web of Science ®Google Scholar
• SkantzeK.MalmU.DenckerSJ.MayPR.CorriganP.Comparison of quality of life with standard of living in schizophrenic outpatients.Br J Psychiatry.19921617978011483165
   PubMed Web of Science ®Google Scholar
• LehmanAF.The well-being of chronic mental patients: assessing their quality of life.Arch Gen Psychiatry.1983403693736838316
   PubMed Web of Science ®Google Scholar
• LehmanAF.The effects of psychiatric symptoms on quality of life assessments among the chronically mentally ill.EvaI Prog Planning.19836143151
   PubMedGoogle Scholar
• SainfortF.BeckerM.DiamondR.Judgments of quality of life of individuals with severe mental disorders: patient self-report versus provider perspectives.Am J Psychiatry.1996 1534975028599397
   PubMed Web of Science ®Google Scholar
• BeckerM.DiamondR.SainfortF.A new patient focused index for measuring quality of life in persons with severe and persistent mental illness.Qual Life Res.199322392518220359
   PubMed Web of Science ®Google Scholar
• AwadAG.VorugantiLNP.HeslegraveRJ.A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation.Qual Life Res.1997621269062438
   PubMed Web of Science ®Google Scholar
• NaberD.MoritzS.LambertM.et al.Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs.Schizophr Res.200150798811378316
   PubMed Web of Science ®Google Scholar
• CarrièreP.BonhommeD.LemperiereT.Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicenter, double-blind study (the Amisulpride Study Group).Eur Psychiatry20001532132911032464
   PubMed Web of Science ®Google Scholar
• ColonnaL.SaleemP.Dondey-NouvelL.ReinW.and the Amisulpride Study Group. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia.Int Clin Psychopharmacol.200015132210836281
   PubMed Web of Science ®Google Scholar
• RosenheckR.CramerJ.XuW.et al.A comparison of clozapine and haloperidol in hospitalised patients with refractory schizophrenia.N Engl J Med,19973378098159295240
   PubMed Web of Science ®Google Scholar
• EssockSM.HargreavesWA.CovellNH.GoetheJ.Clozapine's effectiveness for patients in state hospitals: results from a randomized trial.Psychopharmacol Bull.1996326836978993092
   PubMedGoogle Scholar
• MeltzerHY.BurnettS.BastaniB.RamirezLF.Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients.Hosp Comm Psychiatry.199041892897
   PubMedGoogle Scholar
• StrakowskiSM.JohnsonJL.DelbelloMP.et al.Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode.Schizophr Res.20057816116915950436
   PubMed Web of Science ®Google Scholar
• NaberD.RiedelM.KlimkeA.et al.Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia.Acta PsychiatrScand.2005111106115
   PubMed Web of Science ®Google Scholar
• GinerJ.BobesJ.CerveraS.LealC.BacaE.IbáñezE.Impact of olanzapine on quality of life of patients with schizophrenia: one-year follow-up with the Seville Quality of Life Questionnaire.Actas Esp Psiquiatr.2004321714963775
   PubMed Web of Science ®Google Scholar
• RevickiDA.GendusoLA.HamiltonSH.GanoczyD.BeasleyCM.Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: Quality of life and clinical outcomes of a randomized clinical trial.Qual Life Res.1999841742610474283
   PubMed Web of Science ®Google Scholar
• HamiltonSH.RevickiDA.GendusoLA.BeasleyCM.Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial.Neuropsychopharmacology.19981841499408917
   PubMed Web of Science ®Google Scholar
• MontesJM.CiudadA.GasconJ.GomezJC.and the EFESO Study Group.Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study.Prog Neuro-Psychopharmacol Biol Psychiatry.200327667674
   PubMed Web of Science ®Google Scholar
• GurejeO.MilesW.KeksN.et al.Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand.Schizophr Res.20036130331412729882
   PubMed Web of Science ®Google Scholar
• RitchieCW.ChiuE.HarriganS.et al.The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia.Int J Geriatr Psychiatry.20031843244012766921
   PubMed Web of Science ®Google Scholar
• VorugantiL.CorteseL.OwyeumiL.et al.Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study.Schizophr Res..20025720120812223251
   PubMed Web of Science ®Google Scholar
• HoBC.MillerD.NopoulosP.AndreasenNC.A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia.J Clin Psychiatry.19996065866310549681
   PubMed Web of Science ®Google Scholar
• TranPV.HamiltonSH.KuntzAJ.et al.Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorder.J Clin Psychopharmacol.1997174074189315992
   PubMed Web of Science ®Google Scholar
• HertlingI.PhilippM.DvorakA.et al.Flupenthixol versus risperidone: subjective quality of life as an important factor for comliance in chronic schizophrenic patients.Neuropsychology.2003473746
   Google Scholar
• BobesJ.GutierrezM.GibertJ.GonzalezMP.HerraizL.FernandezA.Quality of life in schizophrenia: long-term follow-up in 362 chronic Spanish schizophrenic outpatients undergoing risperidone maintenance treatment.Eur Psychiatry.19981315816319698620
   PubMed Web of Science ®Google Scholar
• NasrallahHA.DuchesneI.MehnertA.JanagapC.EerdekensM.Healthrelated quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone.J Clin Psychiatry.20046553153615119916
   PubMed Web of Science ®Google Scholar
• VelliganDl.PrihodaTJ.SuiD.RitchJL.MaplesN.MillerAL.The effectiveness of quatiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings.J Clin Psychiatry.20036452453112755654
   PubMed Web of Science ®Google Scholar
• CorriganPW.ReinkeRR.LandsbergerSA.CharateA.ToombsGA.The effects of atypical antipsychotic medications on psychosocial outcomes.Schizophr Res.2003639710112892863
   PubMed Web of Science ®Google Scholar
• HeinrichsDW.HanlonTE.CarpenterWT.The quality of life scale: an instrument for rating the schizophrenic deficit syndrome.Schizophr Bull.1984103883986474101
   PubMed Web of Science ®Google Scholar
• RitsnerM.GibelA.PerelroyzenG.KursR.JabarinM.RatnerY.Quality of life outcomes of risperidone, olanzapine, and typical antipscyhotics among schizophrenia patients treated in routine clinical practice. A naturalistic comparative study.J Clin Psychopharmacol.20042458259115538118
   PubMed Web of Science ®Google Scholar
• HaroJM.EdgellET.NovickD.et al.Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the PanEuropean Schizophrenia Outpatient Health Outcomes (SOHO) study.Acta Psychiatr Scand.200511122023115701107
   PubMed Web of Science ®Google Scholar
• KilianR.DietrichS.ToumiM.AngermeyerMC.Quality of life in persons with schizophrenia in out-patient treatment with first- or second-generation antipsychotics.Acta Psychiatr Scand.200411010811815233711
   PubMed Web of Science ®Google Scholar
• EndicottJ.NeeJ.HarrisonW.et al.Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure.Psychopharmacol Bull.1993293213268290681
   PubMed Web of Science ®Google Scholar
• PrietoL.SacristanJA.HormaecheaJA.CasadoA.BadíaX.GómezJC.Psychometric validation of a generic health-related quality of life measure (EQ-5D) in a sample of schizophrenic patients.Curr Med Res Opin.20032082783515200739
   PubMed Web of Science ®Google Scholar
• LehmanAF.A Quality of Life Interview for the chronically mentally ill (QOLI).Eval Prog Planning.1988115162
   Web of Science ®Google Scholar
• American Psychiatric Association.Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association;1994
   Google Scholar
• MeltzerHY.Dimensions of outcome with clozapine.Br J Psychiatry.1992160(suppl 17)4653
   Web of Science ®Google Scholar
• MeltzerHY.ColaP.WayL.et al.Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia.Am J Psychiatry.1993150163016388105705
   PubMed Web of Science ®Google Scholar
• WareJE.SherbourneCD.The MOS 36-ltem Short-Form Health Survey (SF-36).Med Care.1992304734831593914
   PubMed Web of Science ®Google Scholar
• GinerJ.IbáñezE.BacaE.BobesJ.LealC.CerveraS.Desarrollo del Cuestionario Sevilla de Calidad de Vida (CSCV).Actas Luso-Esp Neurol Psiquiatr.199725(supl. 2)1123
   Google Scholar
• NaberD.A self-rating to measure subjective effects of neuroleptic drug relationships to objective psychopathology, quality of life, compliance, and other clinical variables.Int Clin Psychopharmacol.199510(suppl. 3)1331388866775
   PubMed Web of Science ®Google Scholar
• HeinischM.LudwigM.BullingerM.Psychometric testing of the “Munchner Lebensqualitäts Dimensionen Liste (MLDL). In: Bullinger M, Ludwig M, Steinbüchel V, eds.Lebensqualität bei Kardiovaskulären Erkrankungen. Göttingen, Toronto, Zürich: Hogrefe Verlag für Psychologie,1991
   Google Scholar
• The WHOQOL Group. Development of the World Health Organization WHOQOL-BREF Quality of Life Assessment.Psychol Med.1998285515589626712
   PubMed Web of Science ®Google Scholar
• AndreasenNC.PSYCH-BASE. Iowa City, Ia:The University of Iowa;1989
   Google Scholar
• World Health Organization.The ICD-10 Classification of Mental and Behavioral Disorders. Clinical descriptions and diagnostic guidelines. Geneva, Switzerland: World Health Organization;1992
   Google Scholar
• HellewellJS.Treatment-resistant schizophrenia: reviewing the options and identifying the way forward.J Clin Psychiatry.199960(suppl 23)141910625195
   PubMed Web of Science ®Google Scholar
• LarsonEB.GerlachJ.Subjective experience of treatment, side-effects, mental state and quality of life in cronic schizophrenic and out-patients treated with depot neuropleptics.Acta Psychiatr Scand.1996933813888792909
   PubMed Web of Science ®Google Scholar
• FranzM.LisS.PluddemannK.GallhoferG.Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients.Br J Psychiatry.19971704224259307690
   PubMed Web of Science ®Google Scholar
• LarsenEB.GerlachJ.Subjective experience of treatment, side-effects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics.Acta Psychiatr Scand.1996933813888792909
   PubMed Web of Science ®Google Scholar
• KanedaY.The impact of prolactin elevation with antipsychotic medications on subjective quality of life in patients with schizophrenia.Clinical Neuropharmacology.20032618218412897637
   PubMed Web of Science ®Google Scholar
• AllisonDB.MackellJA.McDonnellDD.The impact of weight gain on quality of life among persons with schizophrenia.Psychiatric Services.20035456556712663847
   PubMed Web of Science ®Google Scholar
• StrassnigM.BrarJS.GanguliR.Body mass index and quality of life in community-dwelling patients with schizophrenia.Schizophr Res.200362737612765746
   PubMed Web of Science ®Google Scholar
• MeyerJM.NasrallahHA.McEvoyJP.et al.The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: Clinical comparison of subgroups with and without the metabolic syndrome.Schizophr Res.20058091816125372
   PubMed Web of Science ®Google Scholar
• OlfsonM.UttaroT.CarsonWH.TafesseE.Male sexual dysfunction and quality of life in schizophrenia.J Clin Psychiatry.20056633133815766299
   PubMed Web of Science ®Google Scholar
• DupuyH.The Psychological General Weil-Being (PGWB) Index. In: Wenger N, Mattson M, Furberg C, et al, eds.Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. Greenwich, CT: Le Jacq;1984
   Google Scholar
• WilkinsonG.HesdonB.WildD.et al.Self-report quality of life measure for people with schizophrenia: the SQLS.Br J Psychiatry.2000177424610945087
   PubMed Web of Science ®Google Scholar
• ClaytonAH.McGarveyEL.ClavetGJ.The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability, and validity.Psychopharmacol Bull.1997337317459493486
   PubMed Web of Science ®Google Scholar
• KatschnigH.How useful is the concept of quality of life in Psychiatry? In: Katschnig H, Freeman H, Sartorius N, eds.Quality of Life in Mental Disorders. Chichester, UK: John Wiley & Sons Ltd;2005317
   Google Scholar